The vast majority of patients who present with pancreatic adenocarcinoma have locally advanced or metastatic disease at the time of presentation without possibility of cure. Although in recent years there have been some new promising chemotherapy regimens that improve overall survival by a few months, the prognosis remains dismal.
There is, however, a subset of patients who experience durable stable disease or partial responses after initial courses of chemotherapy Read more . . .